0.07
-0.0676(-50.87%)
Currency In USD
Address
160 Second Street
Cambridge, MA 02142
United States of America
Phone
617 830 3031
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
April 26, 2010
| Name | Title | Pay | Year Born |
| Mr. Jeffery R. Baxter FCMA | President, Chief Executive Officer & Director | 771,811 | 1961 |
| Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. | Chief Medical Officer | 457,916 | 1955 |
| Dr. David Evander Anderson Ph.D. | Chief Scientific Officer | 473,250 | 1970 |
| Ms. Athena Kartsaklis | Senior Vice President of Finance, Chief Compliance Officer & Principal Financial Officer | 0 | 1965 |
| Mr. John Robert Dillman | Chief Commercial Officer | 0 | 1968 |
| Ms. Nicole Anderson | Director of Corporate Communications & Investor Relations | 0 | N/A |
| Mr. Avi Mazaltov | Global Head of Manufacturing & GM of SciVac | 0 | 1962 |
| Ms. Nell Beattie | Chief Financial Officer, Head of Corporate Development & Director | 0 | 1988 |
| Mr. T. Adam Buckley B.Sc., MBA | Senior Vice President of Business Development | 0 | 1976 |
| Mr. Misha Nossov | Senior Vice President of Global Commercial Supply Strategy & Head of Europe | 0 | N/A |
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.